Status: Recruiting
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis.
Participants needed: 120
Trial details
Phase: Phase 4Age: 40-80Biological sex: AllType: InterventionalSponsor: Matthew J. BudoffUpdated: Oct 15, 2024Locations: 1
Eligibility criteria
Male or female 40 years to 80 years of age at signing of informed consent [+5]
Have had a major cardiovascular event within the last 60 days [+17]